Fennec Pharmaceuticals Inc. (NASDAQ:FENC) reported fourth-quarter results on Tuesday that came in below analyst forecasts, posting a loss of -$0.17 per share compared with the consensus estimate of $0.03. Revenue totaled $13.77 million, also falling short of the analyst estimate of $14.56 million, though it represented a 75% increase from $7.9 million in the fourth quarter of 2024.
Despite the earnings and revenue miss, the company’s shares rose 0.67% in pre-market trading following the announcement, suggesting investors focused more on the company’s longer-term growth outlook.
For the full fiscal year 2025, Fennec reported net product sales of $44.6 million, a 50% year-over-year increase from $29.6 million in 2024.
The company said the growth was driven by expanding use of PEDMARK among both new and existing customers, including multiple adolescent and young adult patients across several tumor types.
“Our 2025 results validate that our strategy is clear and the foundation we built over the past year is now propelling Fennec into its next chapter of growth,” said Jeff Hackman, chief executive officer of Fennec Pharmaceuticals.
Selling and marketing expenses rose to $6.1 million in the fourth quarter from $3.9 million a year earlier, reflecting the expansion of the company’s commercial team. General and administrative expenses increased to $8.9 million from $4.2 million, largely due to higher legal costs related to intellectual property and increased payroll expenses.
Fennec also strengthened its financial position during 2025, raising $42 million through equity offerings and fully paying off its debt. As of December 31, 2025, the company reported $36.8 million in cash and cash equivalents with no outstanding debt.